GlassScriptPrepare for your visit
Jaswinder Singh
Hematology & Oncology · Kansas City, MO · NPI 1093747677
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$46,069.73
in general payments reported to CMS, 2019-2025 · $7,051 in 2025
The $7,051 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Who reported paying
General payments only, top 6 by amount.
- Foundation Medicine, INC. $10,215.81
- Astrazeneca Pharmaceuticals LP $6,046.25
- Celgene Corporation $5,911.49
- Flowonix Medical Incorporated $3,596.53
- Novartis Pharmaceuticals Corporation $1,970.72
- Mylan INC. $1,953.00
Drugs and devices associated with these payments
Keytruda Opdivo Tukysa Jemperli Xtandi Enhertu Venclexta Lenvima Epkinly Talzenna Elahere Zoladex
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Jaswinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/185961/jaswinder-singh